TL;DR
Bispecific antibodies (BsAbs) are engineered proteins that can bind to two different targets simultaneously, offering enhanced therapeutic potential, especially in cancer treatment. This review details the various "IgG-like" formats of BsAbs, focusing on the engineering challenges and solutions for creating these complex molecules, and highlights their promising clinical applications.
What Problem Does This Paper Address?
Cancer remains a leading cause of death, and while traditional monoclonal antibodies have revolutionized treatment, their effectiveness is often limited by tumor heterogeneity and acquired resistance. Bispecific antibodies (BsAbs) offer a solution by enabling simultaneous targeting of multiple pathways or by bridging immune cells to tumor cells, thereby increasing selectivity and efficacy. However, the creation of BsAbs, particularly those with the desirable IgG-like structure (mimicking natural antibodies for better pharmacokinetics and effector functions), presents significant engineering challenges. Specifically, ensuring the correct assembly of two different antibody heavy and light chains into a functional heterodimer, while avoiding mispairing and the formation of non-functional or self-assembled antibodies, is a major hurdle for clinical application and large-scale manufacturing.
Methods
This review focuses on IgG-like bispecific antibody formats, which are engineered to retain the structural and functional advantages of natural IgG antibodies. The paper categorizes these formats into asymmetric and symmetric types, detailing numerous platforms developed to overcome the heterodimerization challenge.
Key methods and platforms discussed include:
- Knobs-into-Holes (KiH): A pioneering technique that modifies the CH3 domains of antibody heavy chains to create complementary "knobs" and "holes," promoting specific heterodimerization.
- CrossMAb: This platform involves exchanging domains between the heavy and light chains of two antibodies to enforce correct assembly.
- Triomab Quadroma: Achieved by fusing hybridoma cells from different antibodies to create a "quadroma" cell line capable of producing BsAbs, with purification strategies leveraging differences in Fc binding.
- FcAAdp (Fc-engineered Asymmetric Dimerization Platform): Utilizes a single common light chain and two distinct heavy chains, with Fc engineering to aid in separating the desired heterodimer.
- Asymmetric Reengineering Technology-Immunoglobulin (ART-Ig): Employs electrostatic steering mutations in the CH3 domain to guide heterodimerization.
- BiMAb: Similar to ART-Ig, it uses electrostatic steering mutations and a common light chain.
- Biclonics: Leverages transgenic mice and electrostatic steering effects for heterodimerization, using a single human common light chain.
- Bispecific Engagement by Antibodies Based on the T Cell Receptor (BEAT): Integrates TCR domains into the CH3 interface to direct heavy chain pairing.
- DuoBody: Based on the natural Fab arm exchange of IgG4 antibodies, this method involves controlled reducing and reoxidizing conditions to promote heterodimerization.
- Azymetric: Employs structure-based rational design and molecular dynamics to engineer specific mutations in the CH3 interface for heterodimerization.
- XmAb: Introduces specific mutations in the CH3-CH3 interface to facilitate HC heterodimerization.
- 2:1 T Cell Bispecific Antibody (2:1 TCB) and 1Fab-IgG TDB: These formats involve specific arrangements of antibody fragments to enhance T cell engagement.
- Dual Variable Domain-Immunoglobulin (DVD-Ig): A symmetric format where variable domains from two antibodies are fused to the N-terminus of an IgG, resulting in tetravalent molecules that bind two antigens.
- FynomAb: Fuses small binding proteins (fynomers) to antibody chains.
- Two-in-One/Dual Action Fab (DAF): Modifies CDRs of antibody light chains to introduce dual specificity.
The review also discusses the mechanisms of BsAbs in tumor therapy, including recruiting and activating immune cells (like T cells and NK cells) and blocking tumor dual signaling pathways.
Datasets
Not discussed in the paper. This paper is a review article summarizing existing technologies and clinical applications, rather than presenting novel experimental data or datasets.
Key Insights and Ideas
- The "mispairing problem" is the central engineering challenge: The core difficulty in creating IgG-like BsAbs lies in ensuring that the correct heavy and light chains from two different antibodies assemble together, rather than forming non-functional homodimers or incorrect heterodimers.
- A diverse toolkit of engineering platforms has emerged: The paper showcases an impressive array of over 23 distinct platforms, each employing clever molecular engineering strategies (e.g., steric hindrance, electrostatic interactions, domain exchange, transgenic systems) to overcome the mispairing issue.
- IgG-like formats offer significant therapeutic advantages: These formats mimic natural antibodies, leading to favorable pharmacokinetics, longer half-lives, and retained effector functions (like ADCC), making them ideal for in vivo therapy.
- Clinical translation is accelerating: The review highlights that over 50 BsAbs are currently in clinical trials, with some already approved, demonstrating the rapid progress from concept to clinical application.
- BsAbs enable multi-pronged attack on cancer: Their ability to target multiple antigens or simultaneously engage tumor cells and immune cells offers a powerful strategy to overcome tumor resistance and heterogeneity, which are limitations of traditional mAbs.
- Symmetric vs. Asymmetric formats offer different trade-offs: While asymmetric formats often focus on precise heavy chain heterodimerization, symmetric formats like DVD-Ig offer tetravalency and simultaneous binding to multiple targets.
Key Results
- Over 23 platforms exist for generating BsAbs: This indicates a mature and rapidly evolving field of antibody engineering.
- 62 BsAb molecules have been developed: A substantial number of bispecific molecules have been engineered.
- More than 50 BsAbs are in clinical trials: This signifies significant progress in translating these engineered antibodies into potential therapeutics.
- Two BsAbs are already approved for clinical use: Catumaxomab (for malignant ascites) and Blinatumomab (for B-cell precursor acute lymphoblastic leukemia) represent successful clinical translations.
- The market for therapeutic BsAbs is projected to grow significantly: Estimated to reach $5.8 billion per year by 2024, underscoring their commercial and therapeutic importance.
- Specific engineering strategies achieve high heterodimerization rates: For example, the KiH technology reported an increase in correct assembly from 57% to 92%.
Limitations and Future Work
- Limitations:
- Complexity of manufacturing: While engineering has advanced, large-scale, cost-effective manufacturing of complex BsAbs remains a challenge.
- Potential for immunogenicity: As with any therapeutic antibody, the risk of eliciting an immune response (HAMA) exists, although some studies suggest it might even be beneficial in certain contexts.
- On-target, off-tumor effects: For solid tumors, identifying truly tumor-specific antigens is crucial to avoid adverse effects on healthy tissues expressing similar targets.
- Future Work:
- Development of novel BsAb formats: Continued innovation in engineering platforms to improve efficiency, stability, and specificity.
- Expansion of clinical applications: Exploring BsAbs for a wider range of cancers and other diseases (autoimmune, infectious).
- Combination therapies: Investigating the synergistic effects of BsAbs with other therapeutic modalities.
- Improving tumor penetration and targeting: Strategies to enhance BsAb delivery and accumulation within solid tumors.
- Personalized BsAb therapies: Tailoring BsAb design to individual patient tumor profiles.
Summary updated